Targeting the Adenosine‐Mediated Metabolic Immune Checkpoint with Engineered Probiotic for Enhanced Chemo‐Immunotherapy
Advanced Science · 2025
DOI: 10.1002/advs.202411813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jinhui Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, IGCME, School of Chemistry, Sun Yat-Sen University, Guangzhou, 510006, China. Hauptthemen laut MEDLINE: Probiotics, Immunotherapy, Tumor Microenvironment, Adenosine. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, China.
Abstract (Originalsprache)
Immunotherapy has revolutionized cancer treatment by leveraging the patient's immune system, yet its efficacy is often hampered by the immunosuppressive tumor microenvironment (TME). Adenosine, a key player in this milieu, suppresses immune cell activity via cAMP signaling. Here, an innovative strategy to remodel the TME using a genetically engineered strain of Escherichia coli Nissle 1917 that expresses adenosine deaminase on its surface under hypoxic conditions is presented. This engineered probiotic targets tumors, converts immunosuppressive adenosine to inosine, and enhances anti‐tumor immune responses. In vivo, the engineered probiotic significantly improved immune cell infiltration and demonstrated synergistic effects with low‐dose doxorubicin in both subcutaneous and orthotopic mouse colorectal cancer model. Furthermore, the engineered probiotic modulated the TME, promoting a shift from M2‐like to M1‐like macrophages and increasing effector T cell populations. These findings highlight the potential of using engineered probiotics for metabolic modulation of the TME, offering a novel approach for enhancing cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, IGCME, School of Chemistry, Sun Yat-Sen University, Guangzhou, 510006, China.
- Guangdong Key Laboratory of Advanced Drug Delivery, School of Bioscience and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
- State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-sen University, Guangzhou, 510060, China.
ORCID-Profile: Zong-Wan Mao, Wei Xia
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province, China
- GBRCE for Functional Molecular Engineering; the Fundamental Research Funds for the Central Universities
Zitieren
APA
Wang, J., Wang, J., Yu, Z., Wen, H., Zhao, C., Zhong, J., Xiao, C., Li, Y., Xu, J., Wang, J., Mao, Z. W., & Xia, W. (2025). Targeting the Adenosine‐Mediated Metabolic Immune Checkpoint with Engineered Probiotic for Enhanced Chemo‐Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202411813
Vancouver
Wang J, Wang J, Yu Z, Wen H, Zhao C, Zhong J, et al. Targeting the Adenosine‐Mediated Metabolic Immune Checkpoint with Engineered Probiotic for Enhanced Chemo‐Immunotherapy. Advanced Science. 2025. doi:10.1002/advs.202411813
BibTeX
@article{Wang2025,
author = {Wang, Jinhui and Wang, Jing and Yu, Zhijie and Wen, Hongyu and Zhao, Chensi and Zhong, Jiayong and Xiao, Chuanle and Li, Yingqiu and Xu, Jianqiao and Wang, Jinquan and Mao, Zong-Wan and Xia, Wei},
title = {Targeting the Adenosine‐Mediated Metabolic Immune Checkpoint with Engineered Probiotic for Enhanced Chemo‐Immunotherapy},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202411813}
}
EUVIMED